Status:
COMPLETED
Probiotics in Intestinal Bacterial Overgrowth
Lead Sponsor:
University of Athens
Conditions:
Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim of the present study is to demonstrate the effect of a mixture of four species of probiotics (Saccharomyces boulardii, Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5 and Lactobac...
Detailed Description
Irritable bowel syndrome (IBS) is the most common gastrointestinal disorder. Pathogenesis remains multifactorial. Better understanding of the interaction of the host with intestinal microbiota the las...
Eligibility Criteria
Inclusion
- Age ≥18 years
- Both genders
- Written informed consent by study participants
- Presence of IBS according to Rome III criteria
- Equal number of SIBO-positive and SIBO-negative patients
Exclusion
- Age \<18 years
- Deny to consent
- Pregnancy or lactation
- Presence of inflammatory bowel disease
- Presence of acute GI tract infection
- Diabetes mellitus type 1 or type 2
- Use of laxatives and antibiotics within the preceding 6 weeks
- Presence of fever, abdominal mass, signs of bowel obstruction and/or leucocytosis
- Abnormal serum levels of thyroid -stimulating hormone.
- History of colon cancer or diverticulitis
- Infection by human immunodeficiency virus (HIV), hepatitis B virus and hepatitis C virus
- Patients with celiac disease defined by biopsy of the duodenal mucosa.
- History of scleroderma and gastroparesis
- Pregnancy or planning pregnancy the next 3 months
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2016
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT02204891
Start Date
September 1 2014
End Date
September 1 2016
Last Update
March 20 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastroenterology, ATTIKON University Hospital
Athens, Attica, Greece, 12462